

continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time.

Background

The Commission instituted these reviews on November 3, 2025 (90 FR 55167, December 1, 2025) and determined on March 6, 2026 that it would conduct expedited reviews (91 FR 18004, April 9, 2026).

The Commission made these determinations pursuant to section 751(c) of the Act (19 U.S.C. 1675(c)). It completed and filed its determinations in these reviews on May 15, 2026. The views of the Commission are contained in USITC Publication 5739 (May 2026), entitled *Oil Country Tubular Goods from China: Investigation Nos. 701-TA-463 and 731-TA-1159 (Third Review)*.

By order of the Commission.

Issued: May 15, 2026.

Sharon Bellamy,

Supervisory Hearings and Information Officer.

[FR Doc. 2026-10002 Filed 5-18-26; 8:45 am]

BILLING CODE 7020-02-P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1447]

Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (“Commission”) has determined not to review an initial determination (“ID”) (Order No. 45) of the presiding Chief administrative law judge (“Chief ALJ”) granting complainant’s unopposed motion to amend the complaint and notice of investigation to reflect respondent Ascendis Pharma, Inc.’s corporate name change to Ascendis Pharma, LLC.

FOR FURTHER INFORMATION CONTACT: Jonathan D. Link, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-3103. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS)

at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on May 8, 2025, based on a complaint filed by BioMarin Pharmaceutical Inc. of Novato, CA (“Complainant”). 90 FR 19532-33 (May 8, 2025). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain drug products containing C-type natriuretic peptide variants and components thereof by reason of infringement of claims 15-20, and 31-48 of RE’267 patent. *Id.* The complaint further alleges that a domestic industry exists. *Id.* The Commission’s notice of investigation named as respondents: Ascendis Pharma, Inc. of Palo Alto, California; Ascendis Pharma A/S of Hellerup, Denmark; Ascendis Pharma Growth Disorders A/S of Hellerup, Denmark (collectively “Ascendis”); and Wacker Biotech GmbH of Jena, Germany. *Id.* The Office of Unfair Import Investigations (“OUII”) is participating in the investigation. *Id.*

On September 12, 2025, the Commission determined not to review Order No. 15 granting Complainant’s motion to amend the complainant and notice of investigation to add Bachem Ag as an additional respondent. *See* Order No. 15 (Aug. 14, 2025), *unreviewed by Comm’n Notice* (Sept. 12, 2025), 90 FR 44843 (Sept. 17, 2025).

On March 23, 2026, the Commission determined not to review an initial determination (Order No. 36) terminating from the investigation claims 15-22, 31, 33, 35-40, 42, 44, and 45-48 of the RE’267 patent, with claims 21-22 having been asserted for domestic industry purposes only. *See* Order No. 36 (Mar. 3, 2026), *unreviewed by Comm’n Notice* (Mar. 23, 2026).

On April 14, 2026, Complainant filed a motion to amend the amended complaint and notice of investigation to reflect respondent Ascendis Pharma, Inc.’s corporate name change to Ascendis Pharma, LLC. No responses to the motion were filed.

On April 27, 2026, the ALJ issued the subject ID (Order No. 45), granting

Complainant’s unopposed motion to amend the amended complaint and notice of investigation. No petitions for review of the ID were filed.

The Commission has determined not to review the subject ID. The notice of investigation is amended to reflect respondent Ascendis Pharma, Inc.’s corporate name change to Ascendis Pharma, LLC.

The Commission vote for this determination took place on May 15, 2026.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: May 15, 2026.

Sharon Bellamy,

Supervisory Hearings and Information Officer.

[FR Doc. 2026-10010 Filed 5-18-26; 8:45 am]

BILLING CODE 7020-02-P

NUCLEAR REGULATORY COMMISSION

[Docket No. M70-7033-ML; ASLBP No. 26-992-01-ML-BD02]

Global Laser Enrichment, LLC; Establishment of Atomic Safety and Licensing Board

Pursuant to the Commission’s regulations, *see, e.g.*, 10 CFR 2.104, 2.105, 2.300, 2.309, 2.313, 2.318, 2.321, notice is hereby given that an Atomic Safety and Licensing Board (Board) is being established to preside over the following proceeding:

GLOBAL LASER ENRICHMENT, LLC (Paducah Laser Enrichment Facility)
Global Laser Enrichment, LLC (GLE) has applied for a license to possess and use special nuclear material for the purpose of constructing and operating a uranium enrichment facility in McCracken County, Kentucky. The requested license would authorize the facility to re-enrich depleted uranium hexafluoride tails and enrich natural-grade uranium hexafluoride to a maximum of 8-weight percent uranium-235 via laser-based isotope separation technology.

Because GLE is seeking authorization to construct a uranium enrichment facility, pursuant to Section 193 of the Atomic Energy Act, as amended (42 U.S.C. 2243), and 10 CFR 70.23a, an uncontested mandatory hearing will be conducted following completion of the NRC staff’s safety evaluation and